معرفی
John C. Affeldt, MD is an Associate Professor in the Department of Ophthalmology at Loma Linda University's School of Medicine. His work focuses on corneal diseases, neurotrophic keratopathy, and infectious ophthalmic conditions. He leads multi-center clinical trials such as the Zoster Eye Disease Study (ZEDS) evaluating antiviral therapies and pivotal trials for recombinant nerve growth factor (cenegermin).
Research Interests:
- Corneal dystrophies and degenerations
- Neurotrophic keratopathy treatment innovations
- Herpes zoster ophthalmicus management
- Ocular surface restoration strategies
- Antiviral and regenerative therapies
Recent Articles Highlight:
Dr. Affeldt's 2025 ZEDS trial publications demonstrate efficacy of valacyclovir in post-herpetic neuralgia. His 2020 cenegermin trial established standards for neurotrophic keratopathy treatment. Earlier work includes defining corneal dystrophy genetic markers and trauma-related ocular injuries.
Grants & Awards:
- NIH-funded ZEDS trial (2018-2024)
- Clarion Biotherapeutics' CSB-001 trial (2023-2024)
- Combangio, Inc. PCED trial (2025-2026)
Labs/Teams: Involved in Loma Linda's Ophthalmology Department research initiatives focusing on translational corneal therapies.
